Browse Studies — Arctuva

Phase 3

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study With Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and…

AsthmaEosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilic Syndrome (HES)

Estimated

~$10 – $7,500

AstraZenecaNCT07444567

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophil…

EosinophiliaHypereosinophilic Syndrome

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00091871

Phase 3

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)

This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving sta…

Hypereosinophilic Syndrome

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT05334368

Phase 2

A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

Background: Hypereosinophilic syndrome (HES) is a blood disorder that causes high levels of white blood cells called eosinophils. HES can damage the lungs and…

Hypereosinophilic Syndrome

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT06477653